Eye on FDA

MARCH 30, 2022

Tectonic pandemic plates are shifting respecting the COVID-19 pandemic. First, government funding supporting access to vaccination and treatment for COVID has run out and so far, is not replenished. Third, the BA.2 For weeks now we have been watching caseloads in the United States broadly fall. 2 wave in the U.S.

Vaccination 76

Vaccination Vaccine Development 76

pharmaphorum

OCTOBER 5, 2021

The EMA has given the go-ahead to the use of Pfizer and BioNTech’s COVID-19 vaccine Comirnaty as a booster for all people aged 18 or more, but says EU member states must decide for themselves whether to make a third dose available to their citizens. More evidence of waning immunity?

Vaccination 52

Vaccination Vaccine Antibody Regulation 52

The Pharma Data

DECEMBER 3, 2020

The Pfizer – BioNTech and Moderna ’s COVID-19 vaccines are currently being reviewed for possible Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA). The downgrade of this year’s 100-million-dose goal to 50 million was caused by supply-chain issues.

Vaccination 52

Vaccination Vaccine Manufacturing Development 52

The Pharma Data

DECEMBER 11, 2020

Food and Drug Administration is expected to approve emergency use of Pfizer’s coronavirus vaccine as early as Saturday after its advisory panel cleared the way for the start of a national campaign to inoculate Americans and stem the spread of COVID-19. The emergency approval comes not a moment too soon.

Vaccination 52

Vaccination Vaccine Doctors Doctor 52

The Pharma Data

DECEMBER 23, 2020

We are now in the 50th week of the Covid-19 pandemic and the situation worldwide shows that there have been 75,479,471 confirmed cases and 1,686,267 deaths, according to the World Health Organisation. A watershed moment for Pfizer and BioNTech as they announced Covid-19 vaccine was 90 per cent efficient.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

Delveinsight

DECEMBER 15, 2020

Gannex received US FDA fast track designation for its NASH drug, ASC42 an FXR Agonist. Gannex Pharma has received Fast Track designation approval from FDA for its drug candidate ASC42 for non-alcoholic steatohepatitis (NASH). Sold under the name Jakafi, it is FDA-approved for the treatment of polycythemia vera (PV) in adults.

Vaccination 54

Vaccination Vaccine Gene Therapy Gene 54

Pfizer

JULY 26, 2022

Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design.

Vaccination 111

Vaccination Vaccine Protein Immune Response 111

Pfizer

JULY 8, 2022

FDA Approval of their COVID-19 Vaccine COMIRNATY® For Adolescents 12 through 15 Years of Age. FDA Approval of their COVID-19 Vaccine COMIRNATY® For Adolescents 12 through 15 Years of Age. The vaccine was previously made available to this age group in the U.S. Fri, 07/08/2022 - 11:48.

FDA Approval 102

FDA Approval Vaccination Vaccine Clinical Trials 102

Pfizer

JULY 19, 2022

1 Adapted Bivalent Vaccine Candidate. Tue, 07/19/2022 - 11:22. 1 Adapted Bivalent Vaccine Candidate. Tuesday, July 19, 2022 - 01:45pm. NEW YORK and MAINZ, GERMANY, July 19, 2022 — Pfizer Inc. 1 as compared to the companies’ current COVID-19 vaccine. Indication & Authorized Use.

Vaccination 100

Vaccination Vaccine Medicine Clinical Trials 100

The Pharma Data

FEBRUARY 1, 2021

HOUSTON, TX, February 01, 2021 /24-7PressRelease/ — It has been just over a year since the COVID-19 virus arrived in the United States, already claiming the lives of over 400,000 Americans. Medical professionals are desperately seeking effective treatments as hospitals are continuously overwhelmed with COVID-19 patients.

Antibody 52

Antibody Protein Vaccination Vaccine 52

Pfizer

JANUARY 27, 2023

Pfizer Responds to Research Claims carterda Fri, 01/27/2023 - 19:48 Pfizer Responds to Research Claims Friday, January 27, 2023 - 08:00pm Share New York, N.Y., In the ongoing development of the Pfizer-BioNTech COVID-19 vaccine, Pfizer has not conducted gain of function or directed evolution research. and around the world.

Research 112

Research Vaccination Vaccine Drugs 112

The Pharma Data

JANUARY 4, 2021

HOUSTON, TX, January 04, 2021 /24-7PressRelease/ — Around the country and especially in Texas, positive COVID-19 cases continue to break records seemingly every day. Other blood centers in California, the state which currently has the highest number of COVID-19 infections in the country, are battling a similar issue.

Containment 52

Containment Antibody Development Vaccination 52

Pfizer

JULY 8, 2022

Pfizer and BioNTech Submit a Variation to EMA for the Vaccination of Children 6 Months to less than 5 Years with COMIRNATY®. Pfizer and BioNTech Submit a Variation to EMA for the Vaccination of Children 6 Months to less than 5 Years with COMIRNATY®. Fri, 07/08/2022 - 09:45. Friday, July 08, 2022 - 11:00am.

Vaccination 81

Vaccination Vaccine Clinical Trials Clinical Trials 81

The Pharma Data

JANUARY 12, 2021

Doses are being supplied for use pursuant to the FDA Emergency Use Authorization for high-risk patients with mild to moderate COVID-19 in order to reduce the risk of progression to severe COVID-19 and/or hospitalization. New agreement covers 1.25 supply to over 1.5 million doses.

Antibody 52

Antibody Production Manufacturing Clinical Trials 52

Pfizer

SEPTEMBER 28, 2022

5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age. 5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age. 5-adapted bivalent COVID-19 vaccine for children 5 through 11 years of age. 5-adapted bivalent vaccine, and preclinical data from the companies’ Omicron BA.4/BA.5-adapted

Vaccination 101

Vaccination Vaccine Medicine Clinical Trials 101

The Pharma Data

DECEMBER 20, 2020

Food and Drug Administration (FDA) is plenty busy with COVID-19 vaccine Emergency Use Authorizations (EUAs) this month, but they’re also wrapping up the year with a few PDUFA dates for other therapies. The FDA completed a class 2 response in July 2020. Here’s a look.

In-Vitro 52

In-Vitro FDA Approval Manufacturing Licensing 52

Pharmaceutical Technology

NOVEMBER 15, 2022

Two weeks ago, the US Centers for Disease Control and Prevention (CDC) director Rochelle Walensky became the latest high-profile individual to report a case of Paxlovid rebound. Similar cases have been in the news for several months as the antiviral’s use increases, but the cause of such effects has remained mostly unknown.

Vaccination 162

Vaccination Vaccine Clinical Trials Clinical Trials 162

Pfizer

SEPTEMBER 16, 2022

Pfizer and BioNTech Receive Positive CHMP Opinion for Conversion of COMIRNATY® Conditional Marketing Authorization to Full Marketing Authorization in the European Union. Standard marketing authorization recommendation applies to all indications and formulations in the European Union, including COMIRNATY® Original/Omicron BA.4-5

Marketing 75

Marketing Vaccination Vaccine Clinical Trials 75

XTalks

DECEMBER 7, 2020

Past Few Weeks Herald Good News on the Vaccine Front. First came the news from Pfizer and its German partner BioNTech that their mRNA vaccine was 90 percent effective in preventing symptomatic COVID-19 disease. No hospitalizations or severe cases of COVID-19 were reported among those receiving the AZD1222 vaccine either.

Vaccination 52

Vaccination Vaccine Development Drugs 52

pharmaphorum

OCTOBER 21, 2021

The FDA has authorised booster shots with Moderna and Johnson & Johnson’s COVID-19 vaccines, a month after giving the go-ahead to a third-dose of Pfizer/BioNTech’s shot. S vaccine, which is initially administered as one rather than two doses. The FDA has followed that advice.

Vaccination 96

Vaccination Vaccine Antibody 96

The Pharma Data

NOVEMBER 20, 2020

(NASDAQ: REGN) today announced that the antibody cocktail casirivimab and imdevimab administered together (formerly known as REGN-COV2 or REGEN-COV2), a therapy currently being investigated for use in COVID-19 , has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA).

Antibody 52

Antibody Production Clinical Trials Clinical Trials 52

XTalks

AUGUST 2, 2023

With each passing year, pharmaceutical companies around the globe strive to deliver cutting-edge medicines, therapies and vaccines that impact the lives of millions. Note: When it comes to companies that report in foreign currencies, the conversion to US dollars utilizes the average annual exchange rates reported by the US Federal Reserve.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

pharmaphorum

FEBRUARY 28, 2021

The FDA has approved emergency use of a third COVID-19 vaccine from Johnson & Johnson’s Janssen Biotech unit, the day after an advisory committee concluded it was safe and effective. The EUA allows the vaccine to be distributed in the U.S for use in individuals 18 years and older.

Vaccination 57

Vaccination Vaccine Immune Response Protein 57

XTalks

JULY 26, 2021

The Centers for Disease Control and Prevention (CDC) has endorsed the J&J/Janssen COVID-19 vaccine, stating that the benefits of the vaccine still outweigh any potential risks. million administered vaccine doses have been reported among those who received the J&J COVID-19 vaccine.

Vaccination 98

Vaccination Vaccine Immune Response Antibody 98

The Pharma Data

NOVEMBER 21, 2020

Authorized for recently diagnosed, mild to moderate COVID-19 in high-risk patients. Food and Drug Administration (FDA). “The science and technology investments Regeneron has made over three decades positioned us to move rapidly to invent, study and maximize production of REGEN-COV2. TARRYTOWN, N.Y. ,

Antibody 40

Antibody Production Clinical Trials Clinical Trials 40

pharmaphorum

JANUARY 9, 2023

Forecasters use terms like “unprecedented,” “inflection point,” and “transformative” when in forward-facing Janus mode. In some ways, it is not difficult to understand why: healthcare faced unprecedented challenge from the COVID-19 pandemic and responded in an extraordinary way. Things fall apart: deglobalisation.

Medicine 90

Medicine Manufacturing Marketing Vaccination 90

Druggist

SEPTEMBER 2, 2021

Amidst the second wave of covid-19 , Ivermectin was a vital part of health discussions conducted by professionals. Post analysis, the evaluation resulted in favor of Ivermectin; many states have already included this drug in the covid kit. Ivermectin was discovered in 1975, which was launched officially for medical use in 1981.

RNA 52

RNA Medicine Drugs Research 52

Pfizer

NOVEMBER 2, 2022

Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19. Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19. Wed, 11/02/2022 - 15:44.

Vaccination 85

Vaccination Vaccine Clinical Trials Clinical Trials 85

Druggist

SEPTEMBER 2, 2021

Amidst the second wave of covid-19, Ivermectin was a vital part of health discussions conducted by professionals. Post analysis, the evaluation resulted in favor of Ivermectin; many states have already included this drug in the covid kit. Ivermectin was discovered in 1975, which was launched officially for medical use in 1981.

RNA 52

RNA Medicine Drugs Research 52

The Pharma Data

MAY 4, 2021

to $3.65, Primarily Reflecting Updates to Anticipated Contributions from BNT162b2 Partially Offset by Additional R&D Expenses for Vaccines to Protect Against COVID-19 as Well as Other mRNA-Based Development Programs and COVID-19 Antivirals. First-Quarter 2021 Revenues of $14.6 EXECUTIVE COMMENTARY.

Vaccination 40

Vaccination Vaccine Production Sales 40

The Pharma Data

FEBRUARY 24, 2022

The European Commission (EC) will review the CHMP recommendation and is expected to make a final decision on a variation to the Conditional Marketing Authorization in the near future. The COVID-19 vaccine booster for individuals 12 through 15 years of age was already granted Emergency Use Authorization by the U.S.

Vaccination 52

Vaccination Vaccine Production Immune Response 52

The Pharma Data

NOVEMBER 30, 2020

On November 20, Pfizer and BioNTech submitted an application for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) for their COVID-19 vaccine. government’s Operation Warp Speed, have indicated they will begin distribution within 24 hours of authorization.

Vaccination 52

Vaccination Vaccine Regulation Trials 52

Eye on FDA

AUGUST 24, 2020

In normal times, when there is no pandemic threatening our lives and livelihoods, it is essential for FDA to maintain the traditional “gold standard” in relation to the decision-making process for the approval of new treatments.

Vaccination 93

Vaccination Vaccine Antibody Development 93

XTalks

DECEMBER 24, 2020

The year 2020 is certainly one that will go down in the books, thanks — or rather, no thanks — to the COVID-19 pandemic. For example, investment in mRNA vaccines and viral vectors came well before January, many years before it. COVID-19: The Pandemic Timeline and Journey. Here is a review of what 2020 served up.

Life Science 111

Life Science Vaccination Vaccine Gene 111

The Pharma Data

DECEMBER 21, 2020

experts announced Sunday which Americans will be next in line receive a COVID-19 vaccine, health officials worldwide worried about a new strain of coronavirus that appears to spread faster than before. The two latest groups in line for a vaccine number roughly 50 million. MONDAY, Dec. In the United States, New York Gov.

Vaccination 52

Vaccination Vaccine Allergies Protein 52

XTalks

SEPTEMBER 29, 2021

US President Joe Biden rolled up his sleeve yesterday for the third time this year to receive a Pfizer vaccine booster shot. However, the CDC went against ACIP’s advice and backed third doses for all frontline workers and those with high-risk institutional exposures.

Vaccination 94

Vaccination Vaccine Life Science Medicine 94

The Pharma Data

OCTOBER 14, 2020

Food and Drug Administration (FDA) approved Inmazeb (atoltivimab, maftivimab and odesivimab-ebgn) for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including newborns of mothers who have tested positive for the infection. (NASDAQ: REGN) announced today that the U.S. Yancopoulos, M.D., ” .

FDA Approval 52

FDA Approval Antibody Production Trials 52